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A bs tr ac t
Background
The association between aging-related testosterone deficiency and late-onset hypogo-
nadism in men remains a controversial concept. We sought evidence-based criteria 
for identifying late-onset hypogonadism in the general population on the basis of 
an association between symptoms and a low testosterone level.
Methods
We surveyed a random population sample of 3369 men between the ages of 40 and 79 
years at eight European centers. Using questionnaires, we collected data with regard 
to the subjects’ general, sexual, physical, and psychological health. Levels of total tes-
tosterone were measured in morning blood samples by mass spectrometry, and free 
testosterone levels were calculated with the use of Vermeulen’s formula. Data were 
randomly split into separate training and validation sets for confirmatory analyses.
Results
In the training set, symptoms of poor morning erection, low sexual desire, erectile 
dysfunction, inability to perform vigorous activity, depression, and fatigue were sig-
nificantly related to the testosterone level. Increased probabilities of the three sex-
ual symptoms and limited physical vigor were discernible with decreased testoster-
one levels (ranges, 8.0 to 13.0 nmol per liter [2.3 to 3.7 ng per milliliter] for total 
testosterone and 160 to 280 pmol per liter [46 to 81 pg per milliliter] for free tes-
tosterone). However, only the three sexual symptoms had a syndromic association 
with decreased testosterone levels. An inverse relationship between an increasing 
number of sexual symptoms and a decreasing testosterone level was observed. 
These relationships were independently confirmed in the validation set, in which the 
strengths of the association between symptoms and low testosterone levels deter-
mined the minimum criteria necessary to identify late-onset hypogonadism.
Conclusions
Late-onset hypogonadism can be defined by the presence of at least three sexual 
symptoms associated with a total testosterone level of less than 11 nmol per liter 
(3.2 ng per milliliter) and a free testosterone level of less than 220 pmol per liter 
(64 pg per milliliter).
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The clinical importance of an age-related reduction in the testosterone level1-3 remains controversial.4,5 Because of the un-
certainty regarding the nature of testosterone de-
ficiency in aging men,6-9 recent guidelines have 
suggested that so-called late-onset hypogonadism 
be regarded as a clinical and biochemical state 
with advancing age, characterized by particular 
symptoms and a low level of serum testoster-
one.10,11 However, few data on hypogonadism in 
aging men are available4,8,12 because of the lack 
of evidence regarding the exact criteria for identi-
fying testosterone deficiency in older men who do 
not have pathological hypogonadism.6,13 Although 
a familiar array of symptoms typify severe testos-
terone deficiency (total testosterone level, <6 to 
8 nmol per liter [1.7 to 2.3 ng per milliliter]) in 
younger patients, symptoms in aging men are non-
specific and are mimicked by other prevalent dis-
orders. The testosterone level below which symp-
toms of androgen deficiency emerge and adverse 
health outcomes ensue in older men remains un-
clear, and the use of arbitrary thresholds is not 
appropriate.11
We conducted a study in a general population 
of middle-aged and elderly men in order to char-
acterize the clinical symptoms associated with a 
low testosterone level, to identify the thresholds of 
testosterone below which such symptoms become 
increasingly prevalent, and to define essential cri-
teria for the syndrome of late-onset hypogonadism 
on the basis of the presence of symptoms associ-
ated with a low testosterone level.14
Me thods
Study Population
We performed age-stratified, random sampling of 
men participating in the European Male Aging 
Study (EMAS) at eight European centers: Man-
chester, United Kingdom; Leuven, Belgium; Malmö, 
Sweden; Tartu, Estonia; Lodz, Poland; Szeged, 
Hungary; Florence, Italy; and Santiago de Compos-
tela, Spain. Men between the ages of 40 and 79 
years in population or primary care registers were 
invited to undergo health assessment by question-
naire, physical and cognitive performance tests, 
and blood tests for biochemical and hormone mea-
surements. From a total of 8416 invitees, 3369 men 
(mean age, 59.7 years) were recruited without the 
use of specific exclusion criteria. The adjusted mean 
response rate at each center was 43% (range, 24 to 
60). A detailed description of the study design, 
recruitment, and methods has been reported pre-
viously.14 Ethics approval for the study was ob-
tained in accordance with local institutional re-
quirements at each center, and written informed 
consent was obtained from all subjects.
Questionnaires
We collected data regarding sociodemographic and 
general health status, medical conditions, medi-
cations, and lifestyle with the use of question-
naires in local languages that were completed by 
the subjects. Interviewer-assisted questionnaires 
that were administered included the Medical Out-
comes Study 36-Item Short-Form Health Survey 
(SF-36) and the Beck Depression Inventory, as de-
scribed previously,14 and the EMAS Sexual Func-
tion Questionnaire.15
Clinical and Laboratory Assessments
Height, weight, body-mass index, and waist cir-
cumference were measured, as described previous-
ly.14 A single, fasting venous blood sample was 
obtained in the morning (before 10 a.m.). Total 
testosterone was measured by means of gas chro-
matography–mass spectrometry (GC–MS), as de-
scribed by Labrie et al.16 The lower limit of total 
testosterone measurement was 0.17 nmol per liter 
(0.05 ng per milliliter). The coefficients of varia-
tion of testosterone measurements were 2.9% with-
in runs and 3.4% between runs. Sex hormone–
binding globulin was measured on the Modular 
E170 platform immunoassay (Roche Diagnos-
tics), as described previously.17 Free testosterone 
levels were derived from measurements of total 
testosterone, sex hormone–binding globulin, and 
albumin.18
Training and Validation Sets
The cohort was randomly subdivided into a train-
ing set and a validation set (Table 1). The associa-
tions between selected symptoms and testoster-
one level were explored in the training set to 
identify clinical and biochemical criteria for late-
onset hypogonadism. The associations between 
symptoms and a low testosterone level that were 
identified in the training set were then indepen-
dently evaluated in the validation set.
In the training set, 32 items from the EMAS 
questionnaires were considered as possible can-
didates for symptoms of androgen deficiency on 
the basis of previous recommendations10,11,13 and 
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studies19-22 (for details, see Section 1 in the Sup-
plementary Appendix, available with the full text of 
this article at NEJM.org). All items were screened 
to identify those that were significantly associat-
ed with total or free testosterone levels by means 
of ordinal logistic-regression models (Section 2 in 
the Supplementary Appendix). Only items that 
were significantly associated with total or free 
testosterone levels were selected. Ordinal respons-
es to the selected questions were then dichoto-
mized into symptomatic and asymptomatic cat-
egories. The Mann –Whitney test was used to 
confirm the difference in testosterone levels be-
tween the symptomatic group and the asymptom-
atic group (Table 2, and Fig. 1 in the Supplemen-
tary Appendix).
Statistical Analysis
In the training set, we used locally weighted lin-
ear regression23 to identify threshold levels of 
testosterone below which the probability of a symp-
tom increased above the background prevalence 
in the overall study population. Multiple logistic-
regression models were used with linear-spline 
functions24 for testosterone levels with adjust-
ment for age and study center, to further define 
testosterone threshold levels at which a signifi-
cant change in the likelihood of the symptom 
occurred.
Multiple correspondence analyses25 were car-
ried out in the training set to map associations 
between categorical variables (the presence or ab-
sence of symptoms and a low or normal testos-
terone level) in a two-dimensional space. Close 
proximity and similar directionality of variables 
graphically (from the intersection point of the two 
axes) indicated a clustering of syndromic associa-
tion. Multiple correspondence analyses were then 
performed in the validation set to ascertain wheth-
er the clustering in the training set could be con-
firmed.
As a means of integrating the various criteria 
and thresholds that were developed and refined in 
the training set, we used logistic-regression mod-
els to quantify the strength of associations be-
tween the combination of selected symptoms and 
testosterone levels below defined thresholds. These 
models were then applied to the validation set to 
determine whether the quantified associations 
between symptoms and low testosterone levels 
could be independently confirmed. We used the 
replicable associations between specified combi-
nations of symptoms and testosterone thresholds 
in the validation set as the basis for specifying the 
minimal criteria for the syndrome of late-onset 
hypogonadism. As an additional internal valida-
tion of the results, we used resampling techniques 
to derive bootstrap confidence intervals for odds 
ratios. The possible confounding effects of age, 
body-mass index, and the number of coexisting 
illnesses on the association between symptoms 
and a low testosterone level were assessed by mul-
tiple logistic-regression analysis.
R esult s
Study Population
From a total of 3369 study participants, 150 were 
excluded because of known pituitary or testicular 
diseases or current use of medications that could 
affect pituitary or testicular function or sex-steroid 
clearance. These exclusions left 3219 men in the 
analysis sample. The characteristics of these men, 
subdivided into training and validation sets, are 
shown in Table 1.
Associations between Symptoms  
and Testosterone Levels
From an initial pool of 32 candidate symptoms of 
testosterone deficiency that were explored in the 
training set, 9 symptoms were confirmed to be 
related to the total or free testosterone level, with 
significant differences between the symptomatic 
group and the asymptomatic group (Table 2). These 
symptoms included three sexual symptoms (de-
creased frequency of morning erection, decreased 
frequency of sexual thoughts, and erectile dysfunc-
tion), three physical symptoms (an inability to en-
gage in vigorous activity [e.g., running, lifting heavy 
objects, or participating in strenuous sports], an 
inability to walk more than 1 km, and an inabil-
ity to bend, kneel, or stoop), and three psychologi-
cal symptoms (loss of energy, sadness [“down-
heartedness” on questionnaire], and fatigue).
The probability of symptoms increased with 
decreased levels of testosterone (Fig. 1). The 
thresholds for total testosterone were approxi-
mately 8 nmol per liter (2.3 ng per milliliter) for 
a decreased frequency of sexual thoughts, 8.5 nmol 
per liter (2.5 ng per milliliter) for erectile dys-
function, 11 nmol per liter (3.2 ng per milliliter) 
for a decreased frequency of morning erections 
(Fig. 1A), and 13 nmol per liter (3.7 ng per mil-
liliter) for diminished vigor (Fig. 1C); free testos-
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terone thresholds for the three sexual symptoms 
were 160, 280, and 280 pmol per liter (46, 81, and 
81 pg per milliliter), respectively (Fig. 1B), with a 
threshold of 160 pmol per liter for both sadness 
and fatigue (Fig. 1F). No thresholds were identi-
fied for physical symptoms associated with free 
testosterone (Fig. 1D) or psychological symptoms 
associated with total testosterone (Fig. 1E). The 
probability of symptoms was relatively high 
(>0.25), even though testosterone was in the un-
equivocally normal range (Fig. 1A). Only seven 
of the men had total testosterone levels of more 
than 35 nmol per liter (10.1 ng per milliliter), 
which may have given a spurious impression of 
changes in the probability of erectile dysfunction 
with high total testosterone levels (Fig. 1A).
Table 1. Characteristics of the Subjects at Baseline.*
Variable
Training Set
(N = 1610)
Validation Set
(N = 1609)
Age and anthropometric measures
Age — yr 59.7±0.3 59.7±0.3
Height — cm 173.8±0.2 173.7±0.2
Weight — kg 83.4±0.4 83.8±0.4
Body-mass index† 27.6±0.1 27.8±0.1
Waist circumference — cm 98.1±0.3 98.8±0.3
Health status
SF-36 score (high score favorable)
Physical functioning (range, 10–30) 27.2±0.1 27.2±0.1
Physical role (4–20) 17.3±0.1 17.2±0.1
Body pain (2–12) 9.3±0.1 9.4±0.1
General health (5–25) 18.0±0.1 17.9±0.1
Vitality (4–20) 14.9±0.1 15.1±0.1
Social role (2–10) 9.0±0.0 9.0±0.0
Emotional role (3–15) 13.4±0.1 13.4±0.1
Mental health (5–25) 20.4±0.1 20.4±0.1
Score on Beck Depression Inventory (low score favorable; range, 0–63) 6.9±0.2 6.8±0.2
Hormone levels‡
Testosterone
Total — nmol/liter 16.5±0.2 16.6±0.2
Free — pmol/liter 293.0±2.2 291.6±2.2
Sex hormone–binding globulin — nmol/liter 42.4±0.5 43.2±0.5
Lifestyle variables
Sexual-partner status — no./total no. (%)
Partner 1410/1551 (90.9) 1449/1565 (92.6)
No partner 141/1551 (9.1) 116/1565 (7.4)
Smoking status — no./total no. (%)
Never smoked 472/1575 (30.0) 461/1577 (29.2)
Former smoker 752/1575 (47.7) 785/1577 (49.8)
Current smoker 351/1575 (22.3) 331/1577 (21.0)
Alcohol intake — no./total no. (%)
None 247/1600 (15.4) 260/1598 (16.3)
1–4 days/wk 970/1600 (60.6) 982/1598 (61.5)
≥5 days/wk 383/1600 (23.9) 356/1598 (22.3)
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Logistic regression with linear splines of tes-
tosterone as independent variables showed sig-
nificantly increased odds ratios for sexual and 
physical symptoms below testosterone thresholds 
(Section 3 in the Supplementary Appendix). Thus, 
for the symptom of a decreased frequency in 
morning erection, a reduction of 1 nmol per liter 
(0.29 ng per milliliter) in total testosterone below 
11 nmol per liter was associated with an odds ratio 
of 1.10 (95% confidence interval [CI], 1.02 to 1.19), 
whereas no significant relationship with the symp-
tom was observed at a total testosterone level 
above 11 nmol per liter. This indicated a total tes-
tosterone threshold for poor morning erection at 
11 nmol per liter, with an apparent plateau effect 
above this threshold. Similarly, a total testoster-
one threshold was identified for a low frequency 
of sexual thoughts at 8.0 nmol per liter and for 
erectile dysfunction at 8.5 nmol per liter; a reduc-
tion of 1 nmol per liter in total testosterone be-
low 8 nmol per liter was associated with an odds 
ratio of 1.48 (95% CI, 1.20 to 1.83) for a low fre-
Table 1. (Continued.)
Variable
Training Set
(N = 1610)
Validation Set
(N = 1609)
Self-reported general health — no./total no. (%)
Excellent or very good 450/1578 (28.5) 443/1595 (27.8)
Good 730/1578 (46.3) 733/1595 (46.0)
Fair or poor 398/1578 (25.2) 419/1595 (26.3)
Body-mass index — no./total no. (%)
<25 410/1576 (26.0) 419/1590 (26.4)
≥25 to <30 790/1576 (50.1) 774/1590 (48.7)
≥30 376/1576 (23.9) 397/1590 (25.0)
Coexisting illness — no./total no. (%)§
Number
0 804/1588 (50.6) 780/1578 (49.4)
1 414/1588 (26.1) 440/1578 (27.9)
≥2 370/1588 (23.3) 358/1578 (22.7)
Type
Heart disease 272/1588 (17.1) 236/1578 (15.0)
Hypertension 451/1588 (28.4) 444/1578 (28.1)
Chronic bronchitis or asthma 120/1588 (7.6) 118/1578 (7.5)
Diabetes 104/1588 (6.5) 132/1578 (8.4)
Prostate disease 165/1588 (10.4) 156/1578 (9.9)
Cancer 87/1609 (5.4) 83/1607 (5.2)
Stroke 63/1609 (3.9) 48/1607 (3.0)
* Plus–minus values are means ±SE. The study population of 3219 men was subdivided into four 10-year age groups 
(40–49 years, 50–59 years, 60–69 years, and 70–79 years) to preserve the age stratification of the study design. In each 
of the four decade samples (Si), two data sets were randomly generated: a training set (Ti) and a validation set (Vi). To 
generate these data sets, each subject from Si was randomly assigned a unique value from a uniformly distributed ran-
dom variable Ui on the interval [0 to 1 ]. The samples were then sorted by Ui into two halves; the first half was selected 
as the training random sample (Ti), and the second half as the validation sample (Vi). The four Ti data sets were then 
combined to form a single training sample of 1610 subjects, and the four Vi data sets were likewise combined to form a 
single validation sample of 1609 subjects. To convert the values for total testosterone to nanograms per milliliter, di-
vide by 3.467. To convert the values for free testosterone to picograms per milliliter, divide by 3.467. SF-36 denotes 
Medical Outcomes Study 36-Item Short-Form Health Survey.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ In the entire analysis sample, the 2.5th and 97.5th percentiles were 7.3 and 30.6 nmol per liter for total testosterone, 
139.6 and 485.5 pmol per liter for free testosterone, and 16.8 and 91.6 nmol per liter for sex hormone–binding globulin.
§ Coexisting illnesses included heart conditions, high blood pressure, stroke, cancer, bronchitis, asthma, peptic ulcer, ep-
ilepsy, diabetes, and diseases of the liver, kidney, and prostate.
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Figure 1. Probability of Symptoms on the Basis of Levels of Total Testosterone and Free Testosterone.
Shown is the age-adjusted probability of the presence of nine symptoms — including sexual symptoms (Panels A and B), physical symp-
toms (Panels C and D), and psychological symptoms (Panels E and F) — in men on the basis of individual levels of total testosterone 
and free testosterone. Threshold testosterone levels, indicated by vertical lines, are shown for symptoms for which the probability was 
significantly increased among men with a decreased testosterone level, as compared with those with an increased level of testosterone. 
No thresholds were identified for physical symptoms associated with free testosterone (Panel D) or for psychological symptoms associ-
ated with total testosterone (Panel E). All values were calculated with the use of locally weighted linear regression. To convert the values 
for total testosterone to nanograms per milliliter, divide by 3.467. To convert the values for free testosterone to picograms per milliliter, 
divide by 3.467.
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quency of sexual thoughts, and such a reduction 
below 8.5 nmol per liter was associated with an 
odds ratio of 1.23 (95% CI, 1.06 to 1.42) for erec-
tile dysfunction. The total testosterone threshold 
for a decreased level of vigorous activity was 13 
nmol per liter; a reduction of 1 nmol per liter in 
total testosterone below 13 nmol per liter was 
associated with an odds ratio of 1.11 (95% CI, 
1.03 to 1.19). Free testosterone thresholds for a 
low frequency of sexual thoughts and for sadness 
were 160 pmol per liter, and the threshold for 
both erectile dysfunction and a decreased fre-
quency of morning erection was 280 pmol per 
liter. The free testosterone threshold for an in-
creased level of fatigue was 160 pmol per liter 
(Section 3 in the Supplementary Appendix).
Clustering of Symptoms with Testosterone
In the training set, multiple correspondence analy-
ses delineated combinations of individual symp-
toms that were associated with one another and 
also with a low or normal testosterone level (Fig. 
2A). Two distinct clusters could be identified. The 
absence of symptoms was clustered with a total 
testosterone level of at least 8.0 nmol per liter, a 
total testosterone level of 11 nmol per liter or 
more, and a free testosterone level of 220 pmol 
per liter or more. The presence of the three sexu-
al symptoms was clustered with a low total tes-
tosterone level (<8 nmol per liter), a total testos-
terone level of less than 11 nmol per liter, and a 
free testosterone level of less than 220 pmol per 
liter in syndromic associations. Symptoms that 
were not in close proximity were not considered 
part of the syndrome of symptomatic low testos-
terone. In the validation set, a very similar pat-
tern was observed, confirming the association be-
tween low total and free testosterone levels and 
the three sexual symptoms (Fig. 2B).
Criteria for Hypogonadism
On the basis of criteria developed in the training 
set, stratification of the number of sexual symp-
toms according to various testosterone thresholds 
revealed a consistent inverse relationship, with an 
increased number of sexual symptoms associated 
with a higher odds ratio for a decreased thresh-
old value for total testosterone (8.0 to 11.0 nmol 
per liter). This association was further strength-
ened by the addition of free testosterone levels to 
the analysis, relationships that were confirmed in 
the validation set (Table 3). The boundaries with-
in which symptoms were significantly associated 
with a low testosterone level in the validation set 
were demarcated by the presence of three sexual 
symptoms and a total testosterone level of less 
than 11 nmol per liter (odds ratio, 1.71; 95% CI, 
1.08 to 2.63). The addition of a threshold of less 
than 220 pmol per liter for free testosterone in-
creased the odds ratio, as compared with the to-
tal testosterone level alone, especially for thresh-
olds between 8.0 and 11 nmol per liter. These 
limits can be regarded as evidence-based criteria 
that are necessary (but not sufficient without the 
ancillary general health information) for the di-
agnosis of late-onset hypogonadism. The associa-
tion between the presence of three sexual symp-
toms and a low testosterone level was attenuated 
by adjustment for age, body-mass index, and the 
number of coexisting illnesses (Table 3).
Estimated Prevalence of Hypogonadism
In this analysis sample, 4.1% of subjects had a 
total testosterone level of less than 8.0 nmol per 
Figure 2 (facing page). Multiple Correspondence Analy-
sis (MCA) Showing Associations between Symptoms 
and Levels of Total Testosterone and Free Testosterone 
in the Training and Validation Sets.
In this MCA plot, variables (including low or normal 
testosterone levels and the presence or absence of 
symptoms) are considered to be highly associated if 
they are at the same distance and in the same direc-
tion from the origin where the horizontal axis (axis 1) 
and the vertical axis (axis 2) cross in the training set 
(Panel A) and the validation set (Panel B). Thus, the 
clustering of the categories of the variables in close 
proximity to one another is indicative of a syndromic 
association, which is highlighted by red circles. The 
values along the axes are indexes of the strength of the 
association between variables. On axis 1, the presence 
of symptoms has positive coordinates (to the right of 
the origin), as compared with the absence of symp-
toms, with negative coordinates (to the left of the ori-
gin). Axis 2 helps identify symptoms that are related to 
a low testosterone level. The red clusters indicate the 
presence of the three sexual symptoms, with coordi-
nates similar to those of a low testosterone level. The 
blue clusters indicate the absence of symptoms, with 
coordinates similar to those of a normal testosterone 
level. In contrast, the three psychological symptoms 
and, to a lesser extent, the three physical symptoms 
are located far from coordinates for normal and low 
testosterone, indicating that these symptoms are unre-
lated or weakly related to the testosterone level. The 
cluster patterns of symptoms in relation to total or free 
testosterone levels in the training set are virtually iden-
tical to those in the validation set. To convert the val-
ues for total testosterone to nanograms per milliliter, 
divide by 3.467. To convert the values for free testoster-
one to picograms per milliliter, divide by 3.467.
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liter, and 17.0% had a total testosterone level of 
less than 11 nmol per liter. If the syndrome of 
late-onset hypogonadism is considered to include 
at least three sexual symptoms associated with a 
total testosterone level of less than 11 nmol per 
liter and a free testosterone level of less than 220 
pmol per liter, among men for whom data were 
available for testosterone levels and questionnaire 
responses, the overall prevalence of late-onset hy-
pogonadism in the EMAS study population would 
be 2.1% (63 of 2966 subjects) and would increase 
with age from 0.1% for men 40 to 49 years of age, 
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to 0.6% for those 50 to 59 years, to 3.2% for 
those 60 to 69 years, and to 5.1% for those 70 to 
79 years (Fig. 2A in the Supplementary Appendix). 
The prevalence of late-onset hypogonadism would 
also rise with an increase in the body-mass index 
and an increasing number of coexisting illnesses 
(Fig. 2B and 2C in the Supplementary Appendix).
Discussion
In this systematic investigation of a large, ran-
dom sample of aging men from the general pop-
ulation, we used a reductive analytic approach to 
produce parsimonious clinical and biochemical 
criteria for diagnosing late-onset hypogonadism. 
Table 3. Odds Ratios for an Association between Sexual Symptoms and a Low Testosterone Level in the Training  
and Validation Data Sets and the Effects of Age, Body-Mass Index, and Coexisting Illness in the Validation Set.*
Variable
Total Testosterone 
<8 nmol/liter†
Total Testosterone  
<8 nmol/liter and  
Free Testosterone 
<220 pmol/liter‡
Total Testosterone 
<11 nmol/liter§
Total Testosterone  
<11 nmol/liter and  
Free Testosterone  
<220 pmol/liter¶
odds ratio (95% CI)
Effect of increasing number of sexual 
symptoms
Training data set
0 Symptoms 1.00 1.00 1.00 1.00
1 Symptom 1.12 (0.52–2.32) 1.32 (0.61–2.88) 1.35 (0.96–1.88) 1.66 (1.09–2.48)
2 Symptoms 1.72 (0.76–3.79) 2.23 (0.83–4.87) 1.40 (0.95–2.13) 2.27 (1.43–3.58)
3 Symptoms 2.39 (1.01–5.01) 3.24 (1.34–6.88) 1.44 (0.91–2.22) 2.63 (1.57–4.27)
Validation data set
0 Symptoms 1.00 1.00 1.00 1.00
1 Symptom 0.98 (0.46–1.98) 1.08 (0.49–2.22) 1.21 (0.88–1.69) 1.09 (0.70–1.63)
2 Symptoms 1.37 (0.54–2.78) 1.71 (0.69–3.67) 1.09 (0.70–1.61) 1.71 (1.03–2.64)
3 Symptoms 3.23 (1.43–6.54) 4.68 (2.08–9.45) 1.71 (1.08–2.63) 3.16 (1.90–5.17)
Effects of age, BMI, and coexisting 
illnesses
Unadjusted analysis
0 Symptoms 1.00 1.00 1.00 1.00
3 Symptoms 3.23 (1.43–6.54) 4.68 (2.08–9.45) 1.71 (1.08–2.63) 3.16 (1.90–5.17)
Analysis adjusted for age
3 Symptoms 3.42 (1.44–7.73) 4.04 (1.84–9.06) 1.95 (1.22–3.12) 2.29 (1.30–3.94)
Analysis adjusted for age and BMI
3 Symptoms 2.37 (0.95–5.20) 2.70 (1.10–6.33) 1.75 (0.99–2.86) 1.89 (1.04–3.50)
Analysis adjusted for age, BMI, and 
no. of coexisting illnesses
3 Symptoms 1.94 (0.74–4.41) 2.24 (0.90–5.10) 1.64 (0.93–2.80) 1.75 (0.96–3.08)
* Low total testosterone was defined as a level below one of two thresholds, either 8 nmol or 11 nmol per liter. Low free 
testosterone was defined as a level below 220 pmol per liter. Bootstrap simulation methods were used to provide confi-
dence intervals for odds ratios. The possible confounding effects of age, body-mass index (BMI), and number of coex-
isting illnesses on the association between symptoms and a low testosterone level were assessed by multiple logistic-
regression analysis. To convert total testosterone values to nanograms per milliliter, divide by 3.467. To convert free 
testosterone values to picograms per milliliter, divide by 3.467.
† The comparator is a total testosterone threshold of 8 nmol per liter or more.
‡ The comparators are a total testosterone threshold of 8 nmol per liter or more and a free testosterone threshold of  
220 pmol per liter or more.
§ The comparator is a total testosterone threshold of 11 nmol per liter or more.
¶ The comparators are a total testosterone threshold of 11 nmol per liter or more and a free testosterone threshold of 
220 pmol per liter or more.
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We observed that many candidate symptoms of 
classic hypogonadism were not associated with 
decreased testosterone levels in older men. Even 
with the nine rigorously selected symptoms, dif-
ferences in mean testosterone levels between 
symptomatic men and asymptomatic men were 
minimal, reflecting the weak overall association 
between symptoms and testosterone levels in this 
population (Fig. 1 in the Supplementary Appendix).
Further analyses revealed nonlinear threshold 
relationships between sexual symptoms and tes-
tosterone at levels around or below the lower limit 
of the eugonadal reference range for young men. 
Thus, sexual symptoms are of diagnostic impor-
tance in elderly men but should suggest andro-
gen deficiency only when testosterone levels are 
clearly subnormal.26 Limited physical vigor was 
significantly associated with a low total testoster-
one level, with an apparent threshold at 13 nmol 
per liter, an observation that is consistent with the 
finding in a previous study of elderly hypogonadal 
patients.22 Psychological symptoms had little or 
no association with the testosterone level, which 
supports the results of some studies27,28 and con-
tradicts the results of another.29 The presence of 
multiple symptom-specific testosterone thresholds 
supports the notion that different functional 
thresholds exist for the various androgen-depen-
dent targets22,30,31 (Fig. 3A and 3B in the Supple-
mentary Appendix).
A consistent syndromic clustering of three sex-
ual symptoms with a low testosterone level can 
clearly be segregated from other, less germane 
symptoms and normal testosterone levels. These 
associations between multiple symptoms and tes-
tosterone thresholds were confirmed and aug-
mented by the inverse dose-dependent relation-
ship between an increasing number of sexual 
symptoms and decreasing threshold levels of tes-
tosterone. The boundaries for a significant asso-
ciation between symptoms and a low testosterone 
level identified the minimum criteria necessary 
to determine the syndrome of late-onset hypogo-
nadism. Our suggested requirement of the pres-
ence of at least three sexual symptoms with a total 
testosterone level of less than 11 nmol per liter and 
a free testosterone level of less than 220 pmol per 
liter supports recommendations in the latest prac-
tice guidelines.10,11 The influence of age, body-
mass index, and number of coexisting illnesses 
on the association between symptoms and testos-
terone level and on the prevalence of late-onset 
hypogonadism is to be expected for a condition 
that develops with aging and is compatible with 
a multifactorial syndrome in which obesity and 
general health contribute to both a low testos-
terone level and symptoms.17,26
In our previously published work involving the 
EMAS cohort, in which we investigated the com-
plex pathogenesis of the age-related decline in 
testosterone, different forms of putative biochem-
ical hypogonadism (designated as primary, sec-
ondary, and compensated) could be distinguished 
in 23.3% of men with the use of only prespeci-
fied hormone criteria, without reference to clin-
ical symptoms.32 This theoretical mechanistic in-
formation contrasts with the data provided by our 
current study, which is aimed at advancing prac-
tical clinical management. Thus, on the basis of 
the systematic determination of total and free tes-
tosterone thresholds below which symptoms be-
came increasingly prevalent, the new data provide 
evidence-based criteria to define and facilitate 
correct diagnosis of the clinical syndrome of late-
onset hypogonadism. Indeed, the prevalence of 
late-onset hypogonadism of 2.1%, as determined 
in our current study, is much lower than that of 
biochemical hypogonadism.2,32 This finding un-
derscores the paramount importance of using not 
only biochemical measures but also stringently 
defined, symptom-based criteria to prevent the 
overdiagnosis of late-onset hypogonadism.
The long list of nonspecific symptoms that have 
a potential association with testosterone deficiency 
makes it difficult to establish a diagnosis of late-
onset hypogonadism. Thus, the prevalence of even 
the most specific sexual symptoms of androgen 
deficiency was relatively high among men with 
unequivocally normal testosterone levels, as re-
ported in previous studies.33-35 This observation 
underscores the importance of specifying the pres-
ence of multiple (at least three) symptoms as a 
diagnostic criterion, preferably with the lower tes-
tosterone threshold (<8.0 nmol per liter), to in-
crease the probability of correctly diagnosing late-
onset hypogonadism.
The addition of the measurement of free tes-
tosterone when the total testosterone level was 
under 8 nmol per liter did not make a substantial 
difference with respect to the association between 
symptoms and testosterone level. This finding is 
similar to those in previous studies22,33,36,37 and 
supports the recommendation that total testos-
terone be used as the primary biochemical crite-
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rion for the diagnosis of late-onset hypogonad-
ism.10,11,13 However, applying the threshold for 
free testosterone may be useful in patients with 
multiple symptoms and a borderline total testos-
terone level (8 to 11 nmol per liter).
We used a current mass spectrometry–based 
method for measuring serum testosterone levels, 
as recommended by the Endocrine Society.38 
Thus, the testosterone thresholds that we estab-
lished should be applicable across laboratories 
with the use of a standard calibrator. However, in 
view of the known concern about the variability 
in and lack of accuracy of platform-based im-
munoassays,38 the proposed testosterone thresh-
olds should be applied only with adjustments 
appropriate to the assay methods used in local 
laboratories.
Our study has certain limitations. The results 
are based on cross-sectional data from question-
naires and a single testosterone measurement in 
men from the general population. It is possible 
that the symptoms we selected had a higher 
specificity in symptomatic clinic patients. Our 
observations should be extrapolated to the diag-
nosis of testosterone deficiency in patients with 
the caveat that a low testosterone level requires 
confirmation with repeated measurement. Fur-
thermore, the documentation of low testosterone 
levels in symptomatic elderly men does not invari-
ably imply that a low testosterone level is the only 
or foremost cause of their symptoms. A compre-
hensive general assessment is required to seek 
potential alternative explanations. These data do 
not set the criteria for initiating testosterone re-
placement, for which clinical trials are required to 
determine the benefits and risks of treatment.
On the basis of data from the general popula-
tion, our study indicated that the presence of three 
sexual symptoms combined with a total testos-
terone level of less than 11 nmol per liter and a 
free testosterone level of less than 220 pmol per 
liter can be considered the minimum criteria for 
the diagnosis of late-onset hypogonadism in ag-
ing men. Our results also highlight the substan-
tial overlap between late-onset hypogonadism and 
nonspecific symptoms of aging. The application 
of these new criteria can guard against the ex-
cessive diagnosis of hypogonadism and curb the 
injudicious use of testosterone therapy in old-
er men.
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